Purdue Pharma Sentenced Ahead of Bankruptcy Over Opioid Crisis Role

RTÉ News reports on the criminal sentencing of Purdue Pharma, the maker of OxyContin, for its central role in the devastating opioid crisis that has plagued the United States. The sentencing comes just ahead of the company's bankruptcy proceedings and impending dissolution, marking a significant, albeit late, reckoning for the pharmaceutical giant and the Sackler family that owned it for decades.

“

These people are not statistics in an epidemiological study.

The scale of the penalties is immense, with Purdue Pharma facing over $8 billion in fines, forfeitures, and penalties. This financial punishment is part of a broader settlement with numerous US states, aiming to provide some measure of compensation to the affected communities and individuals who have suffered due to the opioid epidemic. The article highlights the accusations that Purdue Pharma and other opioid manufacturers engaged in aggressive marketing tactics, downplaying the addictive nature of their products to fuel widespread prescription.

“

failed

US federal judge Madeline Cox Arleo presided over the sentencing, listening for hours to the harrowing testimonies of dozens of victims and their families. Her words conveyed a deep sense of the tragedy, stating that the victims were "not statistics in an epidemiological study" and calling their testimonies "heartbreaking." Judge Arleo also offered an apology on behalf of the US government, acknowledging its failure to protect the public from a company whose practices were "driven by greed" and operated with a "corporate strategy much like a criminal enterprise."

“

driven by greed

Despite many victims urging the rejection of the settlement, primarily because it shields the Sackler family from criminal prosecution, Judge Arleo deemed it the "best route I see among the options before me." The company is scheduled to dissolve on May 1, with its remnants forming Knoa Pharma, a new public benefit company dedicated to providing treatments for opioid use disorder and overdose reversal medications. The article concludes by underscoring the staggering human cost, noting that approximately 806,000 people have died from opioid overdoses in the United States between 1999 and 2023.

“

corporate strategy much like a criminal enterprise